Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
“Exploratory analysis confirmed that high MET expression is a negative prognostic marker for patients treated with erlotinib , indicating that emibetuzumab+erlotinib may provide clinically meaningful benefit.”